COSMIC project: consensus on the objectives of the metabolic syndrome in clinic

References

• Ascaso JF González-Santos P Hernández-Mijares A Diagnosis of metabolic syndrome. Adaptation of diagnostic criteria in our setting. Recommendations of the HDL forum Rev Clin Esp 2006 206 576 582 17178079
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final report Circulation 2002 106 3143 3421 12485966
   PubMed Web of Science ®Google Scholar
• Grundy SM Cleeman JI Daniels SR Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 2005 112 2735 2752 16157765
   PubMed Web of Science ®Google Scholar
• Alberti KG Zimmet P Shaw J Metabolic syndrome: a new worldwide definition. A consensus statement from the International Diabetes Federation Diabet Med 2006 23 469 480 16681555
   PubMed Web of Science ®Google Scholar
• Alberti KG Eckel RH Grundy SM Harmonizing the metabolic syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 2009 120 1640 1645 19805654
   PubMed Web of Science ®Google Scholar
• Estudio Valencia: investigación de la prevalencia de diabetes mel-litus y síndrome metabólico Plan de Diabetes de la Comunitat Valenciana 2006-10 Generalitat Valenciana. Conselleria de Sanitat 2010 Available from: http://publicaciones.san.gva.es/publicaciones/documentos/V.2672-2010.pdf Accessed August 24, 2018
   Google Scholar
• Mottillo S Filion KB Genest J The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis J Am Coll Cardiol 2010 56 1113 1132 20863953
   PubMed Web of Science ®Google Scholar
• Wilson PW D’Agostino RB Parise H Sullivan L Meigs JB Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus Circulation 2005 112 3066 3072 16275870
   PubMed Web of Science ®Google Scholar
• Ford ES Li C Sattar N Metabolic syndrome and incident diabetes: current state of the evidence Diabetes Care 2008 31 1898 1904 18591398
   PubMed Web of Science ®Google Scholar
• Shin JA Lee JH Lim SY Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness J Diabetes Invest 2013 4 334 343
   PubMed Web of Science ®Google Scholar
• Flint TR Fearon DT Janowitz T Connecting the metabolic and immune responses to cancer Trends Mol Med 2017 23 451 464 28396056
   PubMed Web of Science ®Google Scholar
• Lahoz C Vicente I Laguna F García-Iglesias MF Taboada M Mostaza JM Metabolic syndrome and asymptomatic peripheral artery disease in subjects over 60 years of age Diabetes Care 2006 29 148 150 16373915
   PubMed Web of Science ®Google Scholar
• Klein BE Klein R Lee KE Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam Diabetes Care 2002 25 1790 1794 12351479
   PubMed Web of Science ®Google Scholar
• Girman CJ Rhodes T Mercuri M The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Am J Cardiol 2004 93 136 141 14715336
   PubMed Web of Science ®Google Scholar
• Deedwania P Barter P Carmena R Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study Lancet 2006 368 919 928 16962881
   PubMed Web of Science ®Google Scholar
• Scott R Donoghoe M Watts GF Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial Cardiovasc Diabetol 2011 10 102 22104275
   PubMed Web of Science ®Google Scholar
• de Simone G Devereux RB Chinali M Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study Diabetes Care 2007 30 1851 1856 17440172
   PubMed Web of Science ®Google Scholar
• Piepoli MF Hoes AW Agewall S 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J 2016 37 2315 2381 27222591
   PubMed Web of Science ®Google Scholar
• Catapano AL Graham I De Backer G 2016 ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Atherosclerosis 2016 253 281 344 27594540
   PubMed Web of Science ®Google Scholar
• Teixeira TF Alves RD Moreira AP Peluzio Mdo C Main characteristics of metabolically obese normal weight and metabolically healthy obese phenotypes Nutr Rev 2015 73 175 190
   PubMed Web of Science ®Google Scholar
• Lioudaki E Vrentzos GE Mavrogeni H Prevalence of metabolic syndrome according to different definitions in a hypertensive population Angiology 2012 63 39 47 21555311
   PubMed Web of Science ®Google Scholar
• Perez-Martinez P Mikhailidis DP Athyros VG Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation Nutr Rev 2017 75 307 326 28521334
   PubMed Web of Science ®Google Scholar
• Stern MP Williams K González-Villalpando C Hunt KJ Haffner S Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004 27 676 681 14988284
   PubMed Web of Science ®Google Scholar
• Ascaso JF Romero P Real JT Lorente RI Martínez-Valls J Carmena R Abdominal adiposity (waist circumference) and its relation to insulin resistance and the metabolic syndrome in a South European population Eur J Intern Med 2003 14 101 106 12719027
   PubMedGoogle Scholar
• Standards of Medical Care in Diabetes-2017 Classification and diagnosis of diabetes Diabetes Care 2017 40 Suppl 1 S11 S24 27979889
   PubMedGoogle Scholar
• Dagenais GR St-Pierre A Gilbert P Comparison of prognosis for men with type 2 diabetes mellitus and men with cardiovascular disease CMAJ 2009 180 40 47 19124789
   PubMed Web of Science ®Google Scholar
• Sattar N Revisiting the links between glycaemia, diabetes and cardiovascular disease Diabetologia 2013 56 686 695 23354123
   PubMed Web of Science ®Google Scholar
• Jellinger PS Handelsman Y Rosenblit PD American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis Endocr Pract 2017 23 Suppl 2 1 87
   PubMed Web of Science ®Google Scholar
• De Natale C Annuzzi G Bozzetto L Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients Diabetes Care 2009 32 2168 2173 19741188
   PubMed Web of Science ®Google Scholar
• Knowler WC Barrett-Connor E Fowler SE Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 2002 346 393 403 11832527
   PubMed Web of Science ®Google Scholar
• Zinman B Wanner C Lachin JM EMPAREG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 2015 373 2117 2128 26378978
   PubMed Web of Science ®Google Scholar
• Marso SP Daniels GH Brown-Frandsen K LEADER Steering Committee; LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 2016 375 311 322 27295427
   PubMed Web of Science ®Google Scholar
• Neal B Perkovic V Mahaffey KW for the CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 2017 377 644 657 28605608
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Tripathy D Schwenke DC Pioglitazone for diabetes prevention in impaired glucose tolerance N Engl J Med 2011 364 1104 1115 21428766
   PubMed Web of Science ®Google Scholar
• Cusi K Orsak B Bril F Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial Ann Intern Med 2016 165 305 315 27322798
   PubMed Web of Science ®Google Scholar
• Le Roux CW Astrup A Fujioka K 3 Years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial Lancet 2017 389 1399 1409 28237263
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X Astrup A Fujioka K A randomized, controlled trial of 3.0 mg of liraglutide in weight management N Engl J Med 2015 373 11 22 26132939
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Prevention or delay of type 2 diabetes Diabetes Care 2017 40 Suppl 1 S44 S47 27979892
   PubMedGoogle Scholar
• Mancia G Fagard R Narkiewicz K 2013 ESH/ESC guidelines for the management of arterial hypertension J Hypertens 2013 31 1281 1357 23817082
   PubMed Web of Science ®Google Scholar
• James PA Oparil S Carter BL 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 2014 311 507 520 24352797
   PubMed Web of Science ®Google Scholar
• Weber MA Schiffrin EL White WB Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension J Hypertens 2014 32 3 15 24270181
   PubMed Web of Science ®Google Scholar
• SPRINT Research Group Wright JTJr Williamson JD Whelton PK A randomized trial of intensive versus standard blood-pressure control N Engl J Med 2015 373 2103 2116 26551272
   PubMed Web of Science ®Google Scholar
• Whelton PK Carey RM Aronow WS 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Hypertension 2018 71 e13 e115 29133356
   PubMed Web of Science ®Google Scholar
• NAVIGATOR Study Group McMurray JJ Holman RR Haffner SM Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 2010 362 1477 1490 20228403
   PubMed Web of Science ®Google Scholar
• Taskinen MR Boren J New insights into the pathophysiology of dyslipidemia in type 2 diabetes Atherosclerosis 2015 239 483 495 25706066
   PubMed Web of Science ®Google Scholar
• The Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease JAMA 2009 302 1993 2000 19903920
   PubMed Web of Science ®Google Scholar
• Holmes MV Ala-Korpela M Smith GD Mendelian randomization in cardiometabolic disease: challenges in evaluating causality Nat Rev Cardiol 2017 14 577 590 28569269
   PubMed Web of Science ®Google Scholar
• HPS3/TIMI55-REVEAL Collaborative Group Effects of anacetrapib in patients with atherosclerotic vascular disease N Engl J Med 2017 377 1217 1227 28847206
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology Circ Res 2016 118 547 563 26892957
   PubMed Web of Science ®Google Scholar
• Chapman MJ Ginsberg HN Amarenco P Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 2011 32 1345 1361 21531743
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG Chapman MJ Ray K Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 2010 1 2844 2853
   Web of Science ®Google Scholar
• Vaverkova H Karasek D Halenka M Cibickova L Kubickova V Inverse association of lipoprotein(a) with markers of insulin resistance in dyslipidemic subjects Physiol Res 2017 66 S113 S120 28379036
   PubMed Web of Science ®Google Scholar
• Vonbank A Saely CH Rein P Zanolin D Drexel H Lipoprotein(a), the metabolic syndrome and vascular risk in angiographied coronary patients J Clin Endocrinol Metab 2016 101 3199 3203 27270474
   PubMed Web of Science ®Google Scholar
• Pedro-Botet J Badimon L PCSK9: structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects Clin Investig Arterioscler 2016 28 Suppl 2 3 8
   Google Scholar
• Guardiola M Plana N Ibarretxe D Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk Clin Sci (Lond) 2015 128 877 882 25649668
   PubMed Web of Science ®Google Scholar
• Ibarretxe D Girona J Plana N Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders Clin Investig Arterioscler 2016 28 71 78
   PubMedGoogle Scholar
• Richard C Couture P Desroches S Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome Br J Nutr 2012 107 705 711 21787450
   PubMed Web of Science ®Google Scholar
• Grundy SM Metabolic syndrome update Trends Cardiovasc Med 2016 26 364 373 26654259
   PubMed Web of Science ®Google Scholar
• Sniderman AD St-Pierre A Cantin B Dagenais GR Depres J-P Lamarche B Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk Am J Cardiol 2003 91 1173 1177 12745098
   PubMed Web of Science ®Google Scholar
• Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia – full report J Clin Lipidol 2014 8 29 60 24528685
   PubMed Web of Science ®Google Scholar
• Marcovina SM Albers JJ Kennedy H Mei JV Henderson LO Hannon WH International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material Clin Chem 1994 40 586 592 8149615
   PubMed Web of Science ®Google Scholar
• Ballantyne CM Raichlen JS Cain VA Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial J Am Coll Cardiol 2008 52 626 632 18702965
   PubMed Web of Science ®Google Scholar
• Pedro-Botet J Pintó X An updated overview of the high intensity lipid lowering therapy in high cardiovascular risk patients Clin Investig Arterioscler 2016 28 19 30
   Google Scholar
• Lee ET Howard BV Wang W Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study Circulation 2006 113 2897 2905 16769914
   PubMed Web of Science ®Google Scholar
• Baigent C Keech A Kearney PM Cholesterol Treatment Trialists’ (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 2005 366 1267 1278 16214597
   PubMed Web of Science ®Google Scholar
• Rubenfire M Brook RD Rosenson RS Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events Am J Med 2010 123 892 898 20920687
   PubMed Web of Science ®Google Scholar
• Bosomworth NJ Approach to identifying and managing atherogenic dyslipidemia. A metabolic consequence of obesity and diabetes Can Fam Physician 2013 59 1169 1180 24235189
   PubMed Web of Science ®Google Scholar
• Jacobson TA Ito MK Maki KC National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-full report J Clin Lipidol 2015 9 129 169 25911072
   PubMed Web of Science ®Google Scholar
• Pyörälä K Ballantyne CM Gumbiner B Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 2004 27 1735 1740 15220255
   PubMed Web of Science ®Google Scholar
• Matsushima T Nakaya N Mizuno K The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study J Cardiovasc Pharmacol Ther 2012 17 153 158 22573644
   PubMed Web of Science ®Google Scholar
• Sniderman AD Furberg CD Keech A Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment Lancet 2003 361 777 780 12620753
   PubMed Web of Science ®Google Scholar
• Stein EA Sniderman A Laskarzewski P Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B Am J Cardiol 2005 96 36K 43K
   Web of Science ®Google Scholar
• Ballantyne CM Bertolami M Hernandez Garcia HR Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II Am Heart J 2006 151 975 983 16644314
   PubMed Web of Science ®Google Scholar
• Salas-Salvadó J Guasch-Ferré M Estruch R Clish CB Ros E Protective effects of the Mediterranean diet on type 2 diabetes and metabolic syndrome J Nutr 2016 146 Suppl 920S 927S
   Google Scholar
• Stone NJ Robinson J Lichtenstein AH 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 2014 63 2889 2934 24239923
   PubMed Web of Science ®Google Scholar
• Rosen JB Ballantyne CM Hsueh WA Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk Lipids Health Dis 2015 14 103 26336957
   PubMed Web of Science ®Google Scholar
• Brinton EA Maki KC Jacobson TA Sponseller CA Cohen JD Metabolic syndrome is associated with muscle symptoms among statin users J Clin Lipidol 2016 10 1022 1029 27578135
   PubMed Web of Science ®Google Scholar
• Hoy SM Pitavastatin: a review in hypercholesterolemia Am J Cardiovasc Drugs 2017 17 157 168 28130659
   PubMed Web of Science ®Google Scholar
• Pintó X Trias Vilagut F Rius Taruella J Mairal Sallán E Dyslipidemia management in patients with high cardiovascular risk in Spain. ALMA study Aten Primaria 2018 50 35 43 28619533
   PubMed Web of Science ®Google Scholar
• Pedro-Botet J Barrios V Pascual V Delphi consensus on management of dyslipidaemia in patients with impaired glucose metabolism: Diana study Clin Investig Arterioscler 2016 28 132 140
   Google Scholar
• Masana L Ascaso JF Civeira F Sociedad Española de Arteriosclerosis Consensus document of the Spanish Society of Arteriosclerosis on indications of inhibitors of PCSK9 Clin Investig Arterioscler 2016 28 164 165
   Google Scholar
• Ascaso JF Millán J Hernández-Mijares A Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis Clin Investig Arterioscler 2017 29 86 91
   Web of Science ®Google Scholar
• Jakob T Nordmann AJ Schandelmaier S Ferreira-González I Briel M Fibrates for primary prevention of cardiovascular disease events Cochrane Database Syst Rev 2016 11 CD009753 27849333
   PubMedGoogle Scholar
• Wang D Liu B Tao W Hao Z Liu M Fibrates for secondary prevention of cardiovascular disease and stroke Cochrane Database Syst Rev 2015 10 CD009580
   Google Scholar
• Anand SS Yi Q Gerstein H Study of Health Assessment and Risk in Ethnic Groups; Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease Circulation 2003 108 420 425 12860914
   PubMed Web of Science ®Google Scholar
• Faber DR de Groot PG Visseren FL Role of adipose tissue in haemostasis, coagulation and fibrinolysis Obes Rev 2009 10 554 563 19460118
   PubMed Web of Science ®Google Scholar
• Alessi MC Juhan-Vague I Metabolic syndrome, haemostasis and thrombosis Thromb Haemost 2008 99 995 1000 18521499
   PubMed Web of Science ®Google Scholar
• Kostapanos MS Florentin M Elisaf MS Mikhailidis DP Hemostatic factors and the metabolic syndrome Curr Vasc Pharmacol 2013 11 880 905 24168445
   PubMed Web of Science ®Google Scholar
• Kraja AT Province MA Arnett D Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? Nutr Metab (Lond) 2007 4 28 18154661
   PubMed Web of Science ®Google Scholar
• Samad F Ruf W Inflammation, obesity, and thrombosis Blood 2013 122 3415 3422 24092932
   PubMed Web of Science ®Google Scholar
• Rao AK Freishtat RJ Jalagadugula G Alterations in insulin-signaling and coagulation pathways in platelets during hyperglycemia-hyperinsulinemia in healthy non-diabetic subject Thromb Res 2014 134 704 710 25042561
   PubMed Web of Science ®Google Scholar
• Ay C Tengler T Vormittag R Venous thromboembolism: a manifestation of the metabolic syndrome Haematologica 2007 92 374 380 17339187
   PubMed Web of Science ®Google Scholar
• Elbatarny HS Netherton SJ Ovens JD Ferguson AV Maurice DH Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases Eur J Pharmacol 2007 558 7 13 17207790
   PubMed Web of Science ®Google Scholar
• Vaduganathan M Alviar CL Arikan ME Platelet reactivity and response to aspirin in subjects with the metabolic syndrome Am Heart J 2008 156 1002 19061719
   PubMed Web of Science ®Google Scholar
• Bladbjerg EM Larsen TM Due A Jespersen J Stender S Astrup A Postprandial coagulation activation in overweight individuals after weight loss: acute and long-term effects of a high-monounsaturated fat diet and a low-fat diet Thromb Res 2014 133 327 333 24369828
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ (ATT) Collaboration Baigent C Blackwell L Collins R Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 2009 373 1849 1860 19482214
   PubMed Web of Science ®Google Scholar
• Newman JD Schwartzbard AZ Weintraub HS Goldberg IJ Berger JS Primary prevention of cardiovascular disease in diabetes mellitus J Am Coll Cardiol 2017 70 883 893 28797359
   PubMed Web of Science ®Google Scholar
• Salas-Salvado J Fernandez-Ballart J Ros E Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year results of the PREDIMED randomized trial Arch Intern Med 2008 168 2449 2458 19064829
   PubMed Web of Science ®Google Scholar
• Babio N Toledo E Estruch R Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial CMAJ 2014 186 E649 E657 25316904
   PubMed Web of Science ®Google Scholar
• Tobias DK Chen M Manson JE Ludwig DS Willett W Hu FB Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis Lancet Diabetes Endocrinol 2015 3 968 979 26527511
   PubMed Web of Science ®Google Scholar
• Steffen LM Van Horn L Daviglus ML A modified Mediterranean diet score is associated with a lower risk of incident metabolic syndrome over 25 years among young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study Br J Nutr 2014 112 1654 1661 25234439
   PubMed Web of Science ®Google Scholar
• Pucci A Finer N New medications for treatment of obesity: metabolic and cardiovascular effects Can J Cardiol 2015 31 142 152 25661549
   PubMed Web of Science ®Google Scholar
• Mancini MC de Melo ME The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg Diabetol Metab Syndr 2017 9 44 28580018
   PubMed Web of Science ®Google Scholar
• Gloy VL Briel M Bhatt DL Bariatric surgery versus nonsurgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials BMJ 2013 347 f5934 24149519
   PubMed Web of Science ®Google Scholar
• Salas-Salvadó J Bulló M Estruch R Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial Ann Intern Med 2014 160 1 10
   PubMed Web of Science ®Google Scholar
• Davy BM Winett RA Savla J Resist diabetes: a randomized clinical trial for resistance training maintenance in adults with pre-diabetes PLoS One 2017 12 e0172610 28231265
   PubMed Web of Science ®Google Scholar
• Ferrari R Aguiar C Alegria E Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia Eur Heart J Suppl 2016 18 Suppl C C2 C12 28533705
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 2009 150 396 404 19293072
   PubMed Web of Science ®Google Scholar
• Pignone M Alberts MJ Colwell JA American Diabetes Association; American Heart Association; American College of Cardiology Foundation Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation Diabetes Care 2010 33 1395 1402 20508233
   PubMed Web of Science ®Google Scholar
• Goldstein LB Bushnell CD Adams RJ American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research; Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 2011 42 517 584 21127304
   PubMed Web of Science ®Google Scholar
• Lev EI Solodky A Harel N Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation J Am Coll Cardiol 2010 55 114 121 20117379
   PubMed Web of Science ®Google Scholar